June 27, 2017 | Mitoconix Bio, a budding Israeli biopharmaceutical startup focused on therapies for neurological diseases, has secured $20 million in a Series A funding round led by Remiges Ventures. Founded in 2016 at the FutuRx biotechnology incubator, Mitoconix Bio has developed a unique method of slowing neuro-degenerative diseases using drugs which improve mitochondrial functioning. The company has an exclusive license for the technology behind its lead drug, which was developed by founder Daria Mochly-Rosen at Stanford University. The funding will be used to advance Mitoconix’s treatment of Huntington’s disease.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments